TTBK1 and lymphoma: - moderate ATP-directed inhibitor of the CK2 holoenzyme (IC50 of 1.24 μM)- reduction of cell viability and proliferation in cancer cell lines, like MCF7, A427, and A431 (10 μM)TTBK1/2 inhibitors- cytotoxic and antitumor effect on L5178Y lymphoma cells (IC50 of 0.23 μg/ml) and on BALB/c mice inoculated with L5178Y- capable to recover the nuclear and mitochondrial integrity in H2O2-induced damaged cells